The ability of mononuclear phagocytes to assemble and acti-
Introduction
Lys-plasminogen, containing an NH2-terminal lysine, is formed from native NH2-terminal glutamic acid plasminogen by plasmin digestion (1) . Although the physiological relevance of this modified zymogen is unknown, it has been shown kinetically to be a more favorable substrate for plasminogen activators (2) than Glu-plasminogen. In addition Lys-plasminogen binds to fibrin with 100-fold greater affinity than Glu-plasminogen (3) . In purified systems, activation of Gluplasminogen yields Lys-plasmin, suggesting that plasminogen activation occurs via formation of a Lys-plasminogen intermediate (4 of patients receiving therapeutic doses of tissue plasminogen activator. They concluded that Lys-plasminogen was not a major physiological intermediate in plasmin formation (5) .
In addition to its role in fibrinolysis, plasmin generation has been postulated to play an important role in biological events such as inflammation (6) , tumor cell invasion and implantation (7), ovulation and implantation (8) , and neurodevelopment (9) . We have hypothesized that plasmin generation in these circumstances may occur on biological surfaces other than fibrin (10) and have demonstrated that plasminogen specifically binds to purified thrombospondin and can be activated with favorable kinetics (10) . In like manner this has been demonstrated for endothelial cell monolayers (1 1) and vascular subendothelial extracellular matrix (12) . As with fibrin, we also demonstrated that the Lys-form of plasminogen bound to thrombospondin to a greater extent than the native Glu-form (13) . In addition our studies suggest that when Gluplasminogen is activated on a matrix or on a thrombospondin coated surface, there is preferential formation of Lys-plasminogen (12, 13) . Recently, it was reported that U937 cells, a human monocytoid cell line derived from a patient with histiocytic lymphoma (14) , possess specific binding sites for both urokinase and plasminogen (15) . In this study we demonstrate that native Glu-plasminogen binds with very low affinity to U937 cells and murine macrophages, while in sharp contrast, Lys-plasminogen binds specifically and with high affinity. Evidence will be presented that Glu-to Lys-plasminogen conversion and Lys-plasminogen to plasmin conversion occurs on the cell surface due to endogenous plasminogen activators. We also demonstrate the presence of Lys-plasminogen on the surface of activated macrophages from the peritoneal cavity of patients with indwelling catheters and from sites of chronic inflammation.
ture plasticware was from Falcon Labware, Becton Dickinson & Co.
(Cockeysville, MD). OCT embedding medium was from Miles Laboratories and the alkaline phosphatase substrates nitroblue tetrazolium and 5-bromo-4-chloro-3-indolyl phosphate from Bio-Rad Laboratories (Richmond, CA).
Purified proteins and antibodies. Plasminogen was prepared from platelet poor plasma by affinity chromotography on lysine-agarose by the method of Deutsch and Mertz (10, 16) . All purification steps were performed in the presence of 0.01% soybean trypsin inhibitor. Lysplasminogen was prepared by limited proteolysis of Glu-plasminogen by plasmin in a molar ratio of 1:50 for 90 min at 370C (17) . Plasmin was then inhibited by the addition of PPACK at l0-4 M and removed by batch adsorption with soybean trypsin inhibitor-agarose beads. The Glu-and Lys-plasminogen preparations were compared by SDS-PAGE with authentic Glu-plasminogen form 1 and Lys-plasminogen form 1 standards which were generously supplied by Dr. F. J. Castellino (Notre Dame University, South Bend, IN). Two additional procedures were carried out to distinguish Glu-plasminogen from Lys-plasminogen. First, the Lys-plasminogen preparation reacted with a monoclonal antibody specific for Lys-plasminogen provided by P. Holvoet, University of Leuven, Leuven, Belgium (5) in an ELISA system, while the Glu-plasminogen did not. Second, fluid phase activation by tissue plasminogen activator (TPA) using the fluorogenic plasmin substrate D-Val-Leu-Lys-7-amino-4-trifluoromethyl coumarin (10) , showed favorable reaction kinetics for Lys-plasminogen but not for Glu-plasminogen. Furthermore, both plasminogen preparations contained < 0.01% plasmin. Recombinant TPA was supplied by Genentech (San Francisco, CA). High molecular weight urokinase (Winkinase; 60,200 U/mg) was from the Sterling-Winthrop Research Institute (Rensselaer, NY). Purified human Lys-plasmin was obtained by activation of purified Lys-plasminogen with insolubilized urokinase as described previously and stored at -70'C in 50% glycerol (18, 19) . Purified protein S was kindly provided by Dr. Charles Esmon (Oklahoma Medical Research Foundation, Oklahoma City, OK). Murine monoclonal antiplasminogen (3642) reactive with both Glu-and Lys-plasminogen was obtained from American Diagnostica (New York, NY), and monoclonal IgG MPWIPG, reactive only with native Glu-plasminogen (20) was a gift of Dr. B. R. Binder (Vienna, Austria). Rabbit antiplasminogen Fab'2 conjugated to alkaline phosphatase was prepared as previously described (10) . Murine monoclonal antimonocyte/macrophage antibodies OKM6 and anti-Leu M3 were obtained from Ortho Diagnostics (Westwood, MA) and Becton Dickinson (Mountain View, CA), respectively, and anti-von Willebrand factor from Cappel Laboratories (Malvern, PA). FITC-conjugated goat antimouse IgG was purchased from Tago Inc. (Burlingame, CA), alkalinephosphatase conjugated goat antimouse IgG was from Cappel and gold-conjugated goat antimouse IgG (aurogold-BL) with silver enhancement reagents were from Janssen Life Sciences (Piscataway, NJ). Biotinylated goat anti-mouse IgG and avidin-horseradish peroxidase development kit was from Vector Laboratories (Burlingame, CA).
Radioisotope labeling. Purified Glu-and Lys-plasminogen and control proteins were labeled with 1251 by the modified chloramine-T method (21) . Specific activity for most studies was 0.5-2.4 X 10-2 4Ci/tg. Cells and cell culture. U937 cells were obtained from Dr. J. Unkeles (Mt. Sinai Medical College, New York) and were maintained in culture in RPMI 1640 medium (M. A. Bioproducts, Walkersville, MD) supplemented with 10% FBS, 2 mM L-glutamine, 50 U/ml penicillin, and 50 ug/ml streptomycin. Cells were subcultured 1:4 three times per week into 75-cm2 flasks. Elicited macrophages were obtained from peritoneal cavities of6-8 wk C57Black female mice (Jackson Laboratories, Mt. Desert Island, ME) as described previously (22) . Cells were harvested in Dulbecco's modified Eagle's medium (DME) containing penicillin and streptomycin, washed, resuspended in DME containing 20% fetal calf serum and dispensed into 24-well sterile plates at 106 cells/well. Wells were then incubated for 2 h and the nonadherent cells were removed by washing three times in DME plus FCS. Adherent cells were counted as previously described (22) 14 ,000 g in a microfuge (Beckman Instruments, Inc., Fullerton, CA). The aqueous phases were removed, the tubes were inverted, and the tips containing the cell pellet were amputated and placed in a gammacounter for measurement of cell-bound radioactivity. To demonstrate reversibility, cells were incubated with '25I-plasminogen for 1 h at 4VC (50 yg/ml), at which point they were washed and resuspended in RPMI/BSA containing 20 mM EACA. Bound and free radioactivity was then measured at timed intervals as above. All points were measured in duplicate and in all cases nonspecific binding was evaluated in separate tubes containing 20 mM EACA. Specificity was also assessed by coincubation experiments in which labeled plasminogen and excess unlabeled plasminogen were added to U937 cells for 1 h at 40C, at which point cell-bound radioactivity was measured as above.
Murine peritoneal macrophages. Tissue culture wells containing adherent macrophages (6-7 X 105/well) were incubated for 2 h in DME containing 2 mg/ml BSA, washed and then incubated for 1 h at 4VC with gentle agitation with radioiodinated ligands in 0.25 ml DME/BSA containing l0-5 M PPACK. Wells were then extensively washed and specific binding measured by elution ofthe bound radioactivity with DME/BSA containing 50 mM EACA. Total bound radioactivity was measured by solubilizing remaining well contents in 0.2 N NaOH. This procedure removed > 99% of the cells and radioactivity. Time course and reversibility experiments were carried out as described for the U937 cells.
Analysis ofcell-bound plasminogen. '25I Glu-or Lys-plasminogen was incubated with 2 X 106 U937 cells as described above at 37°C for 60 min. Included in the reaction mixture were equal volumes ofeither the serine protease inhibitor PPACK (l0-4 M), TPA 10 U/ml, urokinase 10 U/ml, or buffer (PBS). After the incubation period cells were separated from unbound supernatant radioactivity by centrifugation through silicone oil and the cell bound '25I-ligand eluted with 20 mM EACA in 100 ,u Tris buffered saline for 30 min at 37°C. Both the cell bound and free ligands were then analyzed by SDS-PAGE using 7.5% polyacrylamide vertical slab gels. Gels were fixed in methanol/acetic acid, dried and autoradiographs obtained with Kodak XAR-5 film (Eastman Kodak, Rochester, NY). The autoradiographs were scanned in an LKB laser densitometer (model 2202; LKB Instruments, Gaithersburg, MD). Bound and free ligands were also adsorbed to polystyrene microtiter wells by incubation at 4°C for 16 h in carbonate buffer. Monoclonal antibody specific for the Lys-form of plasminogen was added for 2 h at 37°C. After extensive washing the bound antibody was quantified by sequential addition of alkaline-phosphatase goat antimouse IgG and a colorimetric phosphatase substrate (p-nitrophenylphosphate) as previously described (10).
Demonstration ofLys-plasminogen on human tissue macrophages Cell preparation. Peritoneal exudates from patients with end-stage renal disease and indwelling catheters were obtained by centrifugation of 0.4-1.5 liters of peritoneal dialysate at 250 g for 10 min. To minimize ex vivo proteolysis, PPACK (l10-M) was immediately added to the freshly removed dialysate and cells were washed three times in Hepes-buffered saline containing l0-4 M PPACK before analysis by flow cytometry, immunocytology, or immunoblot. In one study 125I-Glu-plasminogen (5.5 x 106 cpm) was added to the dialysate at collec-tion as a tracer, and after completion of all washes and incubations the cell-bound radioactivity was analyzed by SDS-PAGE/autoradiography.
Fresh tissue from patients with chronic inflammatory lesions (pilonidal cyst, an amputated diabetic leg, and inflamed tonsils) were obtained at surgery and snap frozen in OCT medium. 5-,um sections made on a cryostat, mounted on gelatinized glass slides and processed as described below for immunoperoxidase.
Immunofluorescence flow cytometry. Cells were resuspended in PBS containing 4% BSA and goat serum at 1-2 X 10'/ml and incubated with monoclonal antibodies for 1 h at 220C. The cells were then washed three times and resuspended in FITC-goat anti-mouse IgG for 1 h at 220C. After repeated washing, the cells were resuspended in filtered PBS and analyzed using an Epics flow cytometer (Coulter Instruments, Hialeah, FL) equipped with a MDADS data handling computer and an argon laser. A sizing gate was set by examination of both right angle and forward angle light scatter signals from nonstained cells to eliminate granulocytes and small lymphocytes. For each sample 1-10 X I04 cells were counted within this gate.
Immunocytology. Peritoneal cells were incubated as above with monoclonal antibodies, washed and then resuspended in 20 nm goldconjugated goat-anti-mouse IgG for 1 h at 220C. After washing, the cells were resuspended in PBS containing 1% BSA and centrifuged onto poly-L-lysine and gelatin-coated glass slides using a Shandon Cytospin 2 centrifuge (Shandon Southern Instruments, Sewickley, PA). Slides were then fixed in iced methanol/acetone (50:50, vol:vol), silver enhanced using the Janssen EnhanCE kit, and then lightly counterstained with Giems4.
Immunohistology. Frozen sections from surgical specimens containing chronic inflammatory lesions were incubated with monoclonal anti-Lys-plasminogen, anti-LeuM3, or anti-von Willebrand factor and then stained using an avidin-biotin-peroxidase complex (Vector ABC kit). Sections were counterstained with hematoxylin. Immunoblot analysis. Washed peritoneal cells were resuspended in 100 ul Tris-buffered saline containing 50 mM EACA and incubated for I h at 220C. The eluate was separated from the cells by high-speed centrifugation (15, 000 g X 3 min), electrophoresed under nonreducing conditions on SDS-7.5% polyacrylamide gels, and then electrophoretically transferred to nitrocellulose membranes using an LKB Novablot horizontal system. The membranes were incubated in PBS containing 5% nonfat milk and 0.1% NP-40 for I h at 22°C and then in the same buffer containing alkaline phosphatase-conjugated rabbit antiplasminogen Fab'2 for 4 h. After extensive washing the blots were developed with colorimetric substrates.
Results
Specific binding ofLys-plasminogen to U937 cells and murine peritoneal macrophages. '251-Lys-plasminogen bound specifically to murine peritoneal macrophages and to cells of the human monocytoid line U937. Two unrelated labeled control ligands, '25i-albumin and '25I-protein S, were shown in this and prior studies (22) not to bind to these cells. In addition, > 80% of 125I-Lys-plasminogen binding was blocked by a 200-fold molar excess of unlabeled ligand, further demonstrating specificity. As shown in Fig. 1 , '251-Lys-plasminogen bound in a time-dependent and reversible manner to both of these cells at 4°C. Equilibrium was achieved within 30 min for the U937 cells (A) and 40 min for the macrophages (B). For both cell types binding was > 90% reversible at both 4°C and 37°C after reincubation of washed '25I-Lys-plasminogen coated cells in plasminogen-depleted media containing 20 mM EACA.
As shown in Fig. 2 , binding of '251-Lys-plasminogen to U937 cells was concentration-dependent and saturated at -100 ug/ml. In this and all further studies, specific binding was considered as that degree of binding inhibited by 20 mM (23) for nonlinear curve fitting gave the best fit for a single class ofbinding sites. No significant difference was noted in these binding parameters at 370C.
As with U937 cells, we demonstrated specific binding of Lys-plasminogen on the surface of murine peritoneal macrophages. Fig. 3 depicts a typical binding isotherm and shows that specific binding approached saturation at a concentration of -150 1g/ml. Computer-assisted scatchard analysis of the data (inset) gave best fit for two classes of binding site. One, as (25) . EACA titration studies revealed an I50 of 50 iM for Lys-plasminogen binding to U937 cells and 200 AM to macrophages suggesting that this interaction is mediated by the high-affinity lysine-binding site. The significantly higher 150 observed for Glu-plasminogen (> 2 mM) strongly suggests that its binding is mediated by lower affinity lysine-binding sites. Importantly, coincubation experiments with both Lys-and Glu-plasminogen revealed that incubation of 1251I-Lys-plasminogen with a 200-fold molar excess ofGlu-plasminogen had little inhibitory effect on 1251-Lys-plasminogen binding (Fig. 5) . In contrast coincubation of 125I-Glu-plasminogen with a 20-fold molar excess of unlabeled Lys-plasminogen resulted in 90% inhibition of '251I-Glu-plasminogen binding. Therefore, while Lys-plasminogen did compete with Glu-plasminogen for U937 binding sites, Glu-plasminogen failed to compete with Lys-plasminogen.
Surface activation of Glu-and Lys-plasminogen on U937 cells. U937 cells and macrophages secrete both plasminogen activator and plasminogen activator inhibitor (26) , and also express a cellular receptor for urokinase (27, 28) . We therefore studied the molecular form of the bound plasminogen species by SDS-PAGE and autoradiography. Experiments were carried out in the presence and absence of protease inhibitors as well as exogenous plasminogen activators to determine whether cell-bound plasminogen could act as a substrate for plasmin and plasminogen activator. As shown in Fig. 6 Unlabelled plasminogen (molar excess) Figure 5 . converted to Lys-in the presence of 10 U/ml urokinase and almost 100% by 10 U/ml TPA. We identified the molecular plasminogen species by comparison with 1251-conjugated standards (lanes A and F) under nonreducing conditions. In addition the Glu to Lys conversion was confirmed by reactivity with a monoclonal anti-Lys-plasminogen antibody in an ELISA assay. Thus a portion of the EACA eluate from the U937 cells was coated on ELISA plates and probed with the monoclonal anti-Lys-plasminogen antibody. Only those eluates shown in lanes C-E of Fig. 6 reacted with the monoclonal antibody, further confirming Glu-to Lys-plasminogen conversion. Although this assay is not quantitative, the extent of reactivity of the EACA eluates with the monoclonal antiLys-plasminogen antibody paralleled the gel findings in that reactivity was greatest in the sample shown in lane E, followed by lane D and was least for the sample shown in lane C. Identical results were obtained for Lys-plasminogen binding to the cells (Fig. 7) . When Lys-plasminogen was incubated with the cells in the presence of protease inhibitors the bound form (lane B) was identical to that added (lane A). However, in the absence of protease inhibitors (lane C) plasmin was detected (16% conversion). Lanes D and E demonstrate that 24% of the Lys-plasminogen was converted to plasmin by urokinase and 51% by TPA. Plasmin generation was confirmed by the presence of its constituent plasmin light chain on reducing gels (data not shown). No comparable conversion of Glu-to Lys-plasminogen or Lys-plasminogen to plasmin was detected in the supernatants from these binding experiments (i.e., the unbound material).
Surface expression of Lys-plasminogen on human tissue macrophages. To discern whether human tissue macrophages can express Lys-plasminogen on their surfaces, immunofluorescence flow cytometry, immunogold light microscopy, and immunoblot analysis were carried out with macrophages obtained from patients undergoing chronic peritoneal dialysis. Cells were isolated from freshly removed peritoneal dialysates Table I , demonstrated that up to 76% ofa cell population gated to exclude polymorphonuclear cells and small lymphocytes expressed OKM6 antigen, a specific monocyte/macrophage marker (29) . All of the samples within this gated population contained cells reactive with monoclonal anti-Lys-plasminogen antibody. Reactivity ranged from 4 to 29% and was blocked by preincubation of the cells in 50 mM EACA, further demonstrating specificity. Less than 2% of the cells reacted with control antibodies or with a monoclonal To characterize further the molecular form of this bound plasminogen, washed peritoneal exudates were incubated with EACA and the eluate analyzed by immunoblot using a specific rabbit anti-plasminogen Fab'2 conjugated to alkaline phosphatase. Fig. 9 shows one such blot comparing the EACA eluate (lane 3) to authentic Glu-and Lys-plasminogen (lanes I and 2). In this gel system the major glycosylated forms of plasminogen (forms 1 and 2 as described by Castellino [30] Additional studies were performed to address the question ofwhether the cell-bound Lys-plasminogen was the result ofex vivo proteolytic activity. '25I-Glu-plasminogen was added to freshly obtained peritoneal fluid at the time of collection as a tracer and then after carrying the cells through all the washes and incubations described above the cell-associated radioactivity was analyzed by SDS-PAGE/autoradiography. Less than 0.014% of the added radioactivity was cell associated. Prolonged exposure of these gels revealed that this trace bound material comigrated with native Glu-plasminogen (not shown), demonstrating that the immunologically detected Lys-plasminogen seen on these cell surfaces was generated before the collection of the fluid.
In addition fresh frozen sections of human inflammatory tissues were evaluated by immunohistochemical techniques using the Lys-plasminogen specific monoclonal antibody. As shown in Fig. 10 (A) , macrophage-associated Lys-plasminogen Since U937 cells and macrophages have been shown to secrete both plasminogen activators and plasminogen activator inhibitors the biochemical fate of the bound plasminogen was also studied. When '251-Glu-plasminogen was added to U937 cells in the absence of protease inhibitor, Lys-plasminogen was detected on the cell surface. Lys-plasminogen was not detected in the supernatants indicating that this Glu-to Lysplasminogen conversion, catalyzed by endogenous plasminogen activator, probably occurred on the cell surface. Similarly, when 125I-Lys-plasminogen was added to the cells, plasmin was detected on the cell surface, but not in the supernatant. Addition of TPA or urokinase resulted in accelerated Glu-to Lysplasminogen and Lys-plasminogen to plasmin conversion, indicating that the bound species could be readily activated and may be "protected" from cellular plasminogen activator inhibitors produced by these U937 cells (25, 26) .
Since Lys-plasminogen is much more readily activated to plasmin than is Glu-plasminogen, it is logical to assume that in vivo activation of the fibrinolytic system occurs via Lys-plasminogen intermediates. Holvoet et al., using a monoclonal antibody specific for Lys-plasminogen (5), detected measurable levels of circulating Lys-plasmin-antiplasmin complexes in only three of seven patients receiving TPA infusions for thromboembolic disease. The authors concluded that in vivo activation of Glu-plasminogen occurs by cleavage of the Arg 560-Val 561 bond yielding Glu-plasmin and not via formation of Lys-plasminogen as an intermediate. Our results suggest an alternative interpretation that the Lys-plasmin(ogen) generated remained surface-bound to monocytes or endothelial cells and therefore was not measurable in cell-free plasma. We propose that Lys-plasminogen may function preferentially in activation of native plasminogen in close association with specific cell surfaces.
To define the relationships ofthese in vitro experiments to in vivo reality, we have studied human macrophages from inflammatory lesions. Immunocytologic and immunohistologic techniques were used to show that macrophages from peritoneal lavage of patients with indwelling peritoneal catheters (presumably a low-level inflammatory stimulus) and within mononuclear cell infiltrates from fresh frozen surgical specimens obtained from patients with chronic inflammatory lesions expressed Lys-plasminogen on their surfaces. In addition, using monoclonal antibodies specific for Glu-or Lysplasminogen we showed that peritoneal macrophages did not express native Glu-plasminogen. Immunoblot analysis of EACA eluates from these cells also confirmed the presence of Lys-plasminogen, but not Glu-plasminogen.
Flow cytometric analysis of the peritoneal exudates (Table   I) The data presented in these studies show that Lys-plasminogen binds specifically to mononuclear phagocytes in vitro and is expressed on the surface of inflammatory macrophages in vivo. We suggest that this modified zymogen is the surfaceassociated form of plasminogen and may thus play a critical role in plasmin generation on biological surfaces. Plasmin, in addition to its role as initiator of fibrinolysis, has been postulated to participate in biological events requiring cellular migration through tissues, such as the inflammatory response (6) , tumor cell invasion and implantation (7), ovulation and implantation (8) , and neurodevelopment (9) . Recent studies from this laboratory have demonstrated that the endothelial cell membrane is also a site of preferential conversion of Gluto Lys-plasminogen conversion (31) . The 
